May 4, 2017 10:15 AM EDTUpdated 11:42 AM
News Briefing

For­mer GSK can­cer R&D chief Pao­let­ti takes the reins at Gam­maDelta; Blue­print inks big Cam­bridge lease

Shehla Shakoor

Managing Director

→ Pao­lo Pao­let­ti, the for­mer pres­i­dent of GSK’s on­col­o­gy R&D group, has tak­en the helm at Abing­worth-backed Gam­maDelta Ther­a­peu­tics. “I’m ex­treme­ly ex­cit­ed to take …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times